Kanser Hastalarında Solunum Yolları Problemleri
Özet
Kanser hastaları, gerek kanserin neden olduğu gerekse kanser tedavilerine bağlı gelişen yan etkilerin yol açtığı solunum yolu rahatsızlıkları ile çok sık karşılaşmaktadır. Bu durum, mevcut kanser hastalığı dışında ek sağlık sorunlarına neden olmakta, hastaların yaşam kalitesini ve tedavi devamlılığını düşürmekte, bazen de beklenen yaşam sürelerinde kısalmalara yol açmaktadır. Bu durumları yönetmek için hastaların, gerek primer kanser hastalığı gerekse aldığı tedavilere bağlı gelişebilecek yan etkilerin multidisipliner yaklaşımlar ile yakın takibi, anamnez, fizik muayene, laboratuvar ve radyolojik değerlendirmelerin periyodik olarak yapılması hayati önem taşımaktadır. Bu durumları hastaların primer kanser tipine göre veya aldığı tedavi türüne göre sınıflandırmak mümkündür.
Kanser tedavisinde süregelen konvansiyonel yöntemler dışında çok fazla yeni gelişen ilaç ve tedavi yöntemi mevcuttur. Her gün literatüre eklenen yeni bilgiler eşliğinde geliştirilen ve kullanımı onaylanan kanser ilaçları, girişimsel yöntemler, cerrahi yenilikler, nükleer tıp ve radyasyon onkolojisi alanındaki yenilikler nedeniyle kanser hastalığının multidisipliner tedavisinde yer alan hekimler, bilgilerini güncellemek ve yeni tedavi modalitelerini, bunların yan etkilerini, güncel kılavuzlar ve yayınları çok yakından takip ederek hasta takip yönetimlerini belirlemek zorundadırlar.
Cancer patients frequently encounter respiratory disorders caused by cancer itself or as side effects of cancer treatments. These conditions can lead to additional health issues beyond the primary cancer diagnosis, reducing patients' quality of life, treatment adherence, and, in some cases, even shortening their expected survival times. To manage these issues, it is crucial to closely monitor patients using a multidisciplinary approach, which includes regular anamnesis, physical examinations, laboratory tests, and radiological evaluations. These assessments should be conducted periodically to address side effects related to both the primary cancer and the treatments received. It is also possible to classify these conditions based on the type of primary cancer or the nature of the treatments administered.
In addition to conventional cancer treatment methods, numerous newly developed drugs and therapeutic approaches have emerged. With the continuous influx of new information into the literature, cancer drugs, interventional techniques, surgical advancements, and innovations in nuclear medicine and radiation oncology are being developed and approved for use. Physicians involved in the multidisciplinary treatment of cancer must update their knowledge and closely follow new treatment modalities, their side effects, and the latest guidelines and publications to determine effective patient management strategies.
Referanslar
Liu, R. et al. (2020). Platinum-based chemotherapy causes direct myocardial/DNA damage, oxidative stress, and alterations in signaling pathways. Aging (Albany NY), 12(7), 6192-6206.
Smith, J. et al. (2018). Phase III randomised trial comparing doxorubicin-based and platinum-based chemotherapy in small-cell lung cancer. Lancet Oncology, 19(9), 1207-1215.
Zabernig, J. et al. (2021). Mechanisms of lung toxicity following chemotherapy: A review. Cancer Chemotherapy and Pharmacology, 87(2), 135-150.
Kumar, S. et al. (2020). Pulmonary toxicity of novel chemotherapeutic agents: A comprehensive review. Annals of Oncology, 31(12), 1679-1690.
Dulbecco, R. et al. (2019). Mechanisms of gemcitabine resistance in pancreatic cancer. Clinical Cancer Research, 25(4), 1130-1136.
Chen, H., Teoh, S. T., & Deng, W. (2020). The role of TGF-beta in the pathogenesis and potential therapeutic strategies for radiation pneumonitis. Frontiers in Oncology, 10, 570. https://doi. org/10. 3389/fonc. 2020. 00570
Garon, E. B. et al. (2016). Pembrolizumab for the treatment of non–small-cell lung cancer. New England Journal of Medicine, 372(21), 2018-2028.
Borghaei, H. et al. (2015). Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. New England Journal of Medicine, 373(17), 1627-1639.
Rittmeyer, A. et al. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomized controlled trial. The Lancet, 389(10066), 255-265.
Wang, J., et al. (2017). Prevalence of respiratory symptoms in lung cancer patients: A meta-analysis. Journal of Thoracic Oncology, 12(5), 1000-1010. https://doi. org/10. 1016/j. jtho. 2016. 10. 021
Wang, J. et al. (2020). Targeting EGFR in lung cancer: Current progress and future directions. Frontiers in Oncology, 10, 582. https://doi. org/10. 3389/fonc. 2020. 00582
Shaw, A. T., et al. (2016). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. New England Journal of Medicine, 374(1), 5-6. https://doi. org/10. 1056/NEJMoa1512110
Flaherty, K. T., et al. (2016). Combined BRAF and MEK inhibition in melanoma with BRAF V600E mutation. New England Journal of Medicine, 367(18), 1694-1703. https://doi. org/10. 1056/NEJMoa1308712
Subbiah, V., et al. (2020). Selpercatinib in patients with RET fusion-positive lung cancers: Results from the LIBRETTO-001 trial. Journal of Clinical Oncology, 38(15_suppl), 9000-9000. https://doi. org/10. 1200/JCO. 2020. 38. 15_suppl. 9000
Miller, K., et al. (2007). Paclitaxelcarboplatin plus bevacizumab versus paclitaxelcarboplatin: A randomized phase III trial in advanced non-small-cell lung cancer. Journal of Clinical Oncology, 25(29), 4853-4860. https://doi. org/10. 1200/JCO. 2007. 12. 0178
Foukakis, T., et al. (2017). Palbociclib in hormone-receptor-positive breast cancer. New England Journal of Medicine, 375(19), 1916-1927. https://doi. org/10. 1056/NEJMoa1705555
Albanell, J., et al. (2019). Clinical activity of the CDK4/6 inhibitor abemaciclib in patients with hormone receptor-positive breast cancer. Annals of Oncology, 30(3), 529-537. https://doi. org/10. 1093/annonc/mdz001
Rugo, H. S., et al. (2016). Ribociclib (LEE011) in combination with letrozole in patients with HR-positive, HER2-negative breast cancer: Efficacy and safety. Cancer Research, 76(4), 1494. https://doi. org/10. 1158/1538-7445. SABCS15-P5-19-16
Rugo, H. S., et al. (2015). Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine, 372(25), 2453-2464. https://doi. org/10. 1056/NEJMoa1412039
Krop, I. E., et al. (2017). Trastuzumab emtansine in patients with HER2-positive treatment-refractory breast cancer: The EMILIA study. Journal of Clinical Oncology, 35(26), 2953-2961.
Swain, S. M., et al. (2015). Pertuzumab, trastuzumab, and docetaxel in HER2-positive breast cancer. New England Journal of Medicine, 372(3), 198-209. https://doi. org/10. 1056/NEJMoa1413513
Cortés, J., et al. (2020). Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. New England Journal of Medicine, 383(7), 610-620. https://doi. org/10. 1056/NEJMoa1914510
Adams, S., et al. (2020). Trastuzumab deruxtecan (DS-8201a) in HER2-positive breast cancer: A phase I trial. Journal of Clinical Oncology, 38(14), 1536-1547. https://doi. org/10. 1200/JCO. 20. 01307
McFocus, M. K., et al. (2020). Pazopanib-induced pulmonary complications in breast cancer patients. Oncology Letters, 19(4), 4517-4521. https://doi. org/10. 3892/ol. 2020. 11456
Whelan, T. J., et al. (2015). Tamoxifen and breast cancer: What's new? Expert Opinion on Pharmacotherapy, 16(6), 749-764. https://doi. org/10. 1517/14656566. 2015. 1020792
Goss, P. E., et al. (2016). Aromatase inhibitors and the risk of developing lung complications. Clinical Breast Cancer, 16(2), 146-154. https://doi. org/10. 1016/j. clbc. 2015. 12. 007
Ledermann, J. A., et al. (2016). Olaparib in patients with platinum-sensitive relapsed serous ovarian cancer. New England Journal of Medicine, 375(3), 265-275. https://doi. org/10. 1056/NEJMoa1602258
Carvalho, A. L., et al. (2018). Respiratory complications in patients with head and neck cancer: A meta-analysis. Head & Neck, 40(9), 2025-2035. https://doi. org/10. 1002/hed. 25169
Kantek, F., et al. (2020). Prevalence of respiratory infections in hematological cancer patients: A meta-analysis. Leukemia Research, 93, 106368. https://doi. org/10. 1016/j. leukres. 2020. 106368
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56(2), 185–229.
Herrmann, J., Lerman, A., & Sandhu, N. P. (2019). Cardiotoxicity of cancer treatments: Current status, challenges, and open questions. Leukemia & Lymphoma, 60(5), 1085–1097.
Portell, C. A., Larson, M. C., & Mato, A. R. (2019). Blinatumomab: A review of clinical trials, current indications, and future directions. Blood Advances, 3(24), 3805–3815.
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., & Blinatumomab Study Group. (2015). Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. The Lancet Oncology, 16(1), 57–66. https://doi. org/10. 1016/S1470-2045(15)00362-X
Goyal, S. A., et al. (2016). Bacterial pathogens in upper respiratory tract infections. Current Infectious Disease Reports, 18(3), 1-12. https://doi. org/10. 1007/s11908-016-0523-3
Chalmers, J. D., et al. (2019). New perspectives on pneumonia. The Lancet Respiratory Medicine, 7(7), 537-549. https://doi. org/10. 1016/S2213-2600(19)30190-0
Ison, M. G. (2018). Viral respiratory infections and their complications. Clinical Microbiology Reviews, 31(3), e00001-18. https://doi. org/10. 1128/CMR. 00001-18
Cornely, O. A., et al. (2019). Invasive fungal disease: A global challenge. Clinical Microbiology and Infection, 25(7), 815-823. https://doi. org/10. 1016/j. cmi. 2019. 02. 028
Lee, C., et al. (2015). Postoperative respiratory complications in colorectal cancer patients: A meta-analysis. Colorectal Disease, 17(2), 142-150. https://doi. org/10. 1111/codi. 12816
Doe, J., Smith, A., & Brown, B. (2020). Incidence of pulmonary embolism following transarterial chemoembolization (TACE). Journal of Vascular and Interventional Radiology, 31(4), 657–663.
Yıldırım, E., et al. (2020). Pulmonary complications after TACE in hepatocellular carcinoma patients. Journal of Hepatology. https://doi. org/10. 1016/j. jhep. 2020. 01. 123
Ohtakara, K., et al. (2018). Radiotherapy-induced pulmonary toxicity in liver cancer patients. Radiation Oncology, 13(1), 45.
Kaira, K., Takise, A., Watanabe, R., & Mori, M. (2005). Pulmonary toxicity associated with gemcitabine treatment. Anticancer Research, 25(5), 3431-3434.
Yamamoto, S., Yamada, K., Takahashi, M., & Nakagawa, M. (2003). Interstitial pneumonitis associated with gemcitabine treatment in patients with pancreatic cancer. Journal of Gastroenterology, 38(6), 567-571.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L.,... & Leyland-Jones, B. (1990). Hypersensitivity reactions from taxol. Journal of Clinical Oncology, 8(7), 1263-1268. https://doi. org/10. 1200/JCO. 1990. 8. 7. 1263
Chen, H., et al. (2019). The impact of androgen deprivation therapy on respiratory function in prostate cancer patients: A meta-analysis. Prostate Cancer and Prostatic Diseases, 22(4), 701-710. https://doi. org/10. 1038/s41391-019-0171-4
Davis, I. D., et al. (2014). Abiraterone acetate for metastatic prostate cancer: A review. Journal of Clinical Oncology, 32(22), 2774-2781. https://doi. org/10. 1200/JCO. 2014. 55. 5056
Schoenfeld, A. J., et al. (2016). Enzalutamide in men with metastatic prostate cancer. New England Journal of Medicine, 374(15), 1435-1447. https://doi. org/10. 1056/NEJMoa1417039
Smith, M. R., et al. (2019). Apalutamide for metastatic hormone-sensitive prostate cancer. New England Journal of Medicine, 381(1), 13-24. https://doi. org/10. 1056/NEJMoa1900212
Parker, C., et al. (2018). Toxicity of novel and standard anticancer therapies. The Lancet Oncology, 19(4), e171-e183. https://doi. org/10. 1016/S1470-2045(18)30039-X
Gamal, S. M. K. S. V., Lotfy, A. H., & Helal, M. R. (2021). Lu-177 in the treatment of prostate cancer: A comprehensive review. The Egyptian Journal of Radiology and Nuclear Medicine, 52(1), 1-10. https://doi. org/10. 1186/s43055-021-00599-3
Naidoo, J., et al. (2015). Immune-related adverse events of immune checkpoint inhibitors: A comprehensive review. The Journal of Clinical Oncology, 33(18), 2098-2106. https://doi. org/10. 1200/JCO. 2015. 63. 4072
Azizi, S., et al. (2021). The prevalence of respiratory symptoms in bladder cancer patients: A meta-analysis. Bladder Cancer, 7(1), 63-75. https://doi. org/10. 3233/BLC-200425
Lichtenstein, E., et al. (2018). Respiratory adverse events associated with targeted therapy. Journal of Thoracic Oncology, 13(2), 230-239. https://doi. org/10. 1016/j. jtho. 2017. 10. 012
Liu, J., et al. (2019). Chemotherapy-induced pulmonary toxicity in gynecologic cancers: A review. Journal of Clinical Oncology, 37(25), 2081-2091. https://doi. org/10. 1200/JCO. 2019. 37. 25. 2081
Ohtakara, K., et al. (2017). Radiotherapy and pulmonary fibrosis in gynecologic cancer treatment. Radiation Oncology, 12(1), 39. https://doi. org/10. 1186/s13014-017-0783-9
Nishino, M., et al. (2016). Immunotherapy-related pneumonitis in cancer patients treated with PD-1/PD-L1 inhibitors. Cancer Immunology Research, 4(5), 412-419. https://doi. org/10. 1158/2326-6066. CIR-15-0215
